ES2213141T3 - Anticuerpos con especificidad hacia multiples moleculas de adhesion. - Google Patents

Anticuerpos con especificidad hacia multiples moleculas de adhesion.

Info

Publication number
ES2213141T3
ES2213141T3 ES93915132T ES93915132T ES2213141T3 ES 2213141 T3 ES2213141 T3 ES 2213141T3 ES 93915132 T ES93915132 T ES 93915132T ES 93915132 T ES93915132 T ES 93915132T ES 2213141 T3 ES2213141 T3 ES 2213141T3
Authority
ES
Spain
Prior art keywords
selectin
cells
antibody
antigen
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93915132T
Other languages
English (en)
Spanish (es)
Inventor
Mark A. Jutila
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Montana State University
Original Assignee
Montana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Montana State University filed Critical Montana State University
Application granted granted Critical
Publication of ES2213141T3 publication Critical patent/ES2213141T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES93915132T 1992-05-22 1993-05-21 Anticuerpos con especificidad hacia multiples moleculas de adhesion. Expired - Lifetime ES2213141T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88769592A 1992-05-22 1992-05-22
US887695 1992-05-22
US6450593A 1993-05-19 1993-05-19
US64505 1993-05-19

Publications (1)

Publication Number Publication Date
ES2213141T3 true ES2213141T3 (es) 2004-08-16

Family

ID=26744587

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93915132T Expired - Lifetime ES2213141T3 (es) 1992-05-22 1993-05-21 Anticuerpos con especificidad hacia multiples moleculas de adhesion.

Country Status (12)

Country Link
US (1) US5756095A (de)
EP (2) EP1340811A3 (de)
JP (1) JP3512111B2 (de)
KR (1) KR950701681A (de)
AT (1) ATE261493T1 (de)
AU (1) AU682824B2 (de)
CA (1) CA2134966C (de)
DE (1) DE69333447T2 (de)
DK (1) DK0642577T3 (de)
ES (1) ES2213141T3 (de)
PT (1) PT642577E (de)
WO (1) WO1993024614A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
JP2001501612A (ja) * 1996-09-27 2001-02-06 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 虚血性疾患を治療する方法及び発作後の症状を改善する方法
WO1998033526A1 (fr) * 1997-02-03 1998-08-06 Sumitomo Pharmaceuticals Company, Limited Remedes contre la cardiomyopathie
WO1999036564A1 (en) * 1998-01-16 1999-07-22 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
AU2007202323C1 (en) * 2000-06-29 2012-04-12 Abbvie Inc. Dual specificity antibodies and methods of making and using
SK1152003A3 (en) * 2000-06-29 2003-07-01 Abbott Lab Dual specificity antibodies and methods of making and using
US20090304681A1 (en) * 2004-07-29 2009-12-10 Jutila Mark A Methods for the treatment and prevention of infection using anti-selectin agents
EP2267030A1 (de) 2005-08-25 2010-12-29 Repair Technologies, Inc. Vorrichtungen, Zusammensetzungen und Verfahren zum Schutz und zur Reparatur von Zellen und Gewebe
WO2008011094A2 (en) * 2006-07-18 2008-01-24 Robert Sackstein Cytokine induction of selectin ligands on cells
US8324350B2 (en) * 2006-12-29 2012-12-04 Abbott Laboratories Dual-specific IL-1α/IL-1β antibodies
US8147836B2 (en) 2007-12-17 2012-04-03 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
WO2010054393A1 (en) * 2008-11-10 2010-05-14 Mount Sinai School Of Medicine Of New York University Methods of inhibiting inflammation-associated tissue damage by inhibiting neutrophil activity
CA2754635C (en) * 2009-03-06 2018-06-19 Universite Paris Descartes Use of gingival fibroblast conditioned media to treat metastatic cancer
TW201124535A (en) 2009-10-30 2011-07-16 Abbott Lab SORF constructs and multiple gene expression
WO2013059439A2 (en) 2011-10-21 2013-04-25 Dyax Corp. Combination therapy comprising an mmp-14 binding protein
JP5865009B2 (ja) * 2011-10-25 2016-02-17 シスメックス株式会社 活性化好中球の検出方法
CN110023339A (zh) 2016-09-23 2019-07-16 Csl有限公司 凝血因子结合蛋白及其应用
JP7449390B2 (ja) 2020-01-24 2024-03-13 ファイザー・インク 抗ｅ－セレクチン抗体、組成物および使用の方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2606033B1 (fr) * 1986-10-31 1988-12-16 Cird Proteine cytoplasmique des cellules suprabasales de l'epiderme, anticorps capables de reconnaitre cette proteine, et lignees cellulaires hybrides capables de secreter de tels anticorps
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
US4935234A (en) * 1987-06-11 1990-06-19 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US5019648A (en) * 1987-07-06 1991-05-28 Dana-Farber Cancer Institute Monoclonal antibody specific for the adhesion function domain of a phagocyte cell surface protein
US5071964A (en) * 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
US5098833A (en) * 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5002873A (en) * 1989-03-17 1991-03-26 Fred Hutchinson Cancer Research Center DNA sequence encoding a lymphocyte adhesion receptor for high endothelium
US5011778A (en) * 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
US5080883A (en) * 1990-05-11 1992-01-14 Mallinckrodt, Inc. 99 mtcn3s-conjugated anti-bibrin monoclonal antibody as an in vivo diagnostic agent for imaging

Also Published As

Publication number Publication date
EP0642577B1 (de) 2004-03-10
DK0642577T3 (da) 2004-07-19
AU4523293A (en) 1993-12-30
JPH08502242A (ja) 1996-03-12
PT642577E (pt) 2004-08-31
EP0642577A1 (de) 1995-03-15
CA2134966C (en) 2007-03-27
DE69333447D1 (de) 2004-04-15
EP1340811A2 (de) 2003-09-03
WO1993024614A1 (en) 1993-12-09
AU682824B2 (en) 1997-10-23
EP1340811A3 (de) 2003-11-19
JP3512111B2 (ja) 2004-03-29
DE69333447T2 (de) 2009-09-10
US5756095A (en) 1998-05-26
ATE261493T1 (de) 2004-03-15
KR950701681A (ko) 1995-04-28
CA2134966A1 (en) 1993-12-09
EP0642577A4 (en) 1995-04-12

Similar Documents

Publication Publication Date Title
ES2213141T3 (es) Anticuerpos con especificidad hacia multiples moleculas de adhesion.
Andonegui et al. Platelets express functional Toll-like receptor-4
ES2201049T3 (es) Un ligando de selectina.
US6482409B1 (en) Treatment for inflammatory bowel disease with a vcam-1/1gG fusion protein
EP0528931B1 (de) Humanisierte chimäre anti-"icam-1" antikörper, herstellungsverfahren und verwendung
EP0625912B1 (de) Behandlung für entzündungserkrankung des darmes
Lam et al. Recombinant human vimentin binds to P-selectin and blocks neutrophil capture and rolling on platelets and endothelium
CN101720232B (zh) 具有修饰的效应器功能的fc受体结合型多肽
ES2201052T3 (es) Moleculas de adhesion intercelular y sus ligandos de union.
SK77393A3 (en) Pharmaceutical mixture for treatment of illnesses by inhibition of intercellular adhesion by elam-1
CN100360183C (zh) 整联蛋白α4亚单位的拮抗剂在制备治疗纤维变性的药物中的用途
JPH08503617A (ja) Ｌ−セレクチンに反応性のヒト化抗体
US20100279307A1 (en) Angiogenesis Inhibiting Molecules, Their Selection, Production and Their Use in the Treatment of Cancer
Visintini et al. Haemorrhagic cystitis, preventive and treatment interventions in patients undergoing haematopoietic stem cell transplantation: A scoping review
HUT73462A (en) Method for modulating transendothelial migration of cells promoting inflammation, and related methods of measurment thereof
US5169775A (en) Monoclonal antibodies against lymphoma-associated antigens, hybrid cell lines producing these antibodies
Mulligan et al. Cytokine and adhesion molecule requirements for lung injury induced by anti-glomerular basement membrane antibody
CA1340898C (en) Monoclonal antibodies against lymphoma-associated antigens, hybrid cell lines producing these antibodies, and use therefore
WO2024193516A1 (zh) 抗ox40抗体在治疗炎症或免疫性疾病中的应用
Rabb Role of leukocytes and leukocyte adhesion molecules in renal ischemic-reperfusion injury
CN118662628A (zh) 抗ox40抗体在治疗炎症或免疫性疾病中的应用
Manner CD43 Plays Both Antiadhesive and
Walcheck Molecular characterization of the primary adhesion mechanisms that direct [gamma/delta] T cells to epithelial-associated tissues